Rivaroxaban for Slow Coronary Flow After PCI in STEMI

The goal of this clinical trial is to learn if drug Rivaroxaban works to improve slow flow in STEMI patients after PCI in adults. It will also learn about the safety of drug Rivaroxaban. The main questions it aims to answer are: Does drug Rivaroxaban Reduce the Corrected TIMI Frame Count (cTFC) in 1 Week After PCI ? Researchers will compare Combination therapy with rivaroxaban (2.5 mg administered twice daily), aspirin (100 mg administered daily), and clopidogrel (75 mg administered daily) to Dual Antiplatelet Therapy to see if drug Combination therapy with rivaroxaban, aspirin works to treat Slow Flow in STEMI Patients After PCI. Participants will: Take drug Combination therapy with rivaroxaban (2.5 mg administered twice daily), aspirin (100 mg administered daily), and clopidogrel (75 mg administered daily) or Dual Antiplatelet Therapy every day for 1 months. Visit the clinic in 7 days、30 days and 365 days for checkups and tests.

NCT Number	NCT07195812
Lead Sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University Collaborators: Affiliated Hospital of Jiaxing University, The Second Affiliated Hospital of Jiaxing University, Wenzhou People's Hospital
Conditions	ST Elevation Myocardial Infarction, No-Reflow Phenomenon
Enrollment	60 participants
Start Date	2025-10
Primary Completion	2028-05 (estimated)
Study Completion	2028-05 (estimated)
Updated on ClinicalTrials.gov	2025-09-29